Alamar Biosciences 2026 UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good afternoon. My name is Doug Schenkel, and on behalf of UBS, it is my pleasure to welcome Justin McAnear, Chief Financial Officer of Alamar, to the 2026 Healthcare Conference. Alamar is a relatively new issue, really exciting, relatively new entrant to the public company arena. It is a fantastic platform that launched in early 2024, and since then, the company has seen rapid adoption across both the academic and biopharmaceutical end markets. The company reported another strong quarter last week with revenue up, I think it was 68%.
That is right. Not too shabby.
Consumables up 79%, gross margin getting to a record 61.5%. The company also announced major collaborations with the UK Biobank and GSK, and on top of it, you raised your 2026 revenue outlook, so that was a good call. What I was thinking we could do is talk a bit about those developments as a starting point, and then really turn to the more longer-term outlook for durable growth driven by improved installed base economics, content expansion, and a more pronounced move into diagnostics. So, that is the agenda.
That sounds like a great list.
Yeah, let's see what we can do.
Yeah, happy to be here, and thank you very much for having us.
Awesome. Justin, you and I have known each other for a little bit. What attracted you to Alamar, and what about the technology and business opportunity convinced you this was the right place to be?
Well, I think that's a great question. A number of things, actually, and I'll start with the technology. It's truly breakthrough technology, and it takes a novel approach to proteomics that other systems can't replicate, and that NULISA focuses on suppressing the background noise rather than just amplifying the signal. The result is a huge increase in sensitivity. We are the only platform that combines the five pillars of ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range, and seamless automation. Because of that technology, we don't need to make trade-offs across those five as we move to lower plex or higher plex. The technology itself is truly fantastic. The business model was attractive as well.
It's a traditional razor blade business model, where we sell instruments at a list price of $400,000 per instrument. We have a durable consumable business as well, with highly differentiated content on leading the premium side of proteomics. I think the timing was really attractive as well. Advanced proteomics does not have a clear market leader right now, and to come in and be a part of something and be a part of a team that has a novel solution when you're aspiring to go lead that category, that's an exciting place to be. I would say the vision overall. Yuling has a fantastic vision in going from discovery all the way through to clinical applications on the same platform.
It's a strong business today, and there's the potential for a highly durable, much larger business in the future as the company goes through different stages on the way to clinical and diagnostic support.
Actually, sticking with the term durability, I'm sure the team does extensive competitive intelligence work. I mean, as we sit here today, clearly NULISA's sensitivity, specificity, and multiplexing capabilities are far ahead of most in the field. Do you think that those areas of differentiation are going to remain durably intact for the next several years as you look at the competitive landscape?
I do. Because of our unique approach in suppressing the background noise, no other platform approaches the problem quite like this. Like I said, the result is that you can not have to trade off on your ultra-high sensitivity as you move into higher multiplex, and the seamless automation definitely helps as well. As far as the durability over the coming years, we have patent protection. We basically have five years of trade secrets, which would be extremely hard to replicate, built up as well. The result is right now, as we move into advanced proteomics and more interest in being able to detect the lower abundance part of the proteome, we are uniquely positioned to be able to do that because of our high sensitivity and be able to maintain that ultra-high sensitivity in a multiplexed panel.
The market opportunity. You've sized research proteomics as roughly, I think, an $11 billion opportunity over the next decade.
Yeah. How do you get to that number?
As you think about moving into adjacencies, not saying $11 billion isn't big enough, how much bigger can this opportunity get?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
